| Next 10 |
TRVN News and Press, Trevena Inc.
-
Are These On Your List Of Penny Stocks To Buy Or Sell This Week? Last week was one wild week for penny stocks . While I won’t argue that July had been a hot and cold month for small-caps, the final days were definitely some of the most active. It really kicked off with the massive news...
-
Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...
-
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in Chin...
-
Are These Biotech Penny Stocks On Your List Right Now? One of the hottest sectors this year is biotechnology. No matter if you like momentum, speculation, fundamentals, etc. there are plenty of biotech penny stocks to watch in 2020. With that, it’s important to understand some of the ...
-
Westwater Resources (NASDAQ: WWR ) +144% on positive independent test results on ULTRA-PMG. More news on: Westwater Resources, Inc., Tenax Therapeutics, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
-
Trevena (NASDAQ: TRVN ) has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT 1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients. More news on: T...
-
Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients
-- TRV027 is a novel AT 1 receptor selective agonist with the potential to treat acute lung injury and ARDS Robust clinical development history with well-characterized PK and demonstrated safety in ~700 individuals -- CHESTERBROOK, Pa., June 02, 2020 (GLOBE NEWSWIR...
-
Trevena, Inc. (TRVN) Q1 2020 Earnings Conference Call May 07, 2020 08:00 AM ET Company Participants Robert Yoder - Senior Vice President and Chief Business Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Senior Vice President and Chief Medical Offi...
-
The following slide deck was published by Trevena, Inc. in conjunction with their 2020 Q1 earnings Read more ...
-
Trevena (NASDAQ: TRVN ): Q1 GAAP EPS of -$0.06 in-line. More news on: Trevena, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Stock Information
MENU
TRVN
TRVN Quote
TRVN Short
TRVN News
TRVN Articles
Get TRVN Alerts
News, Short Squeeze, Breakout and More Instantly...
-
Are These On Your List Of Penny Stocks To Buy Or Sell This Week? Last week was one wild week for penny stocks . While I won’t argue that July had been a hot and cold month for small-caps, the final days were definitely some of the most active. It really kicked off with the massive news...
-
Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...
-
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in Chin...
Direct Branding and Market Awareness
